's Information

William F. Fearon, MD

Country USA
Specialty Interventional Cardiologist
  1. 3-Year Follow-Up of the FAME 3 Trial
  2. Update on the ALL-RISE Trial (Advancing Cath Lab Results With FFR-Angio Physiology Assessment)
  3. How I Use Angio-Based Physiology to Guide My Case in the Cath Lab: Practical Appraisal
  4. Unmet Need for FFR in LM PCI
  5. True Message from FAME 3
  6. Role of PCI in Multivessel CAD: What Do the New Guidelines Say?
  7. FFR-Guided PCI for Multivessel CAD in 2022
  8. Angiography-derived Coronary Physiology
  9. Complete Revascularization for MVD and LM: Anatomic or Functional Concept
  10. Angio-guided vs. FFR-guided PCI
  11. FAME III: The Lessons from FAME Studies, What We Learned
  12. FAST FFR
  13. Many Pressure Wires in Cath Lab: Advantages and Disadvantages
  14. FAME 2: 3-year Clinical and Cost-effectiveness Outcomes of FFR-guided PCI in Patients with Coronary Artery Disease
  15. Non-Invasive FFR Assessment
  16. FFR Is Still Standard!
  17. Is Anatomic Complete Revascularization Really Necessary?
  18. PCI vs. CABG in LM and MVD: Time to Apply FFR for Decision-Making: Updated Data and FAME-3
  19. Post-PCI FFR: What Does It Mean and Should We Measure It?
  20. Are We Ready to Move from FFR to Resting Indices?
  21. The FUTURE Trial and Current Evidence of FFR Guided PCI: Is There Warning Sign?
  22. Routine Assessment of the Microcirculation and Absolute Flow: A Glimpse to the Future
  23. FFR Is Underutilized - Beyond Just Intermediate Lesions!
  24. Left Main
  25. Coronary Blood Flow, Pressure and Resistance: How to Integrate, Interpret and Apply in Practice
  26. Update on FAME 3 Trial
  27. Who Needs Adenosine or iFR, I Have cFFR (Contrast FFR): Update on the CONTRAST Study
  28. Invasive Evaluation of the Patient with Chest Pain and No Obstructive CAD
  29. Integrated Use of IMR and FFR in Daily Practice
  30. The Ultimate: FAME 3
  31. FFR State-of-the-Art: Clinical Applications and New Technologies
  32. MVD and FAME Studies
  33. Practical Set-up
  34. Update of the FAME 3 Trial
  35. Experimental Basis and Clinical Validation of FFR
  36. Assessment and Clinical Relevance of Coronary Microvasculature
  37. For Ischemia, Forget VP and Focus on the Ischemic Lesion!
  38. [FFR Use at CathLab: More & Better] Unmet Need: FAME 3
  39. FFR Clinical Trials: Review and Update
  40. FFR Evaluation: Optimal Measurement and Common Mistakes
  41. Clinical Benefit of FFR
  42. Tips and Trick
  43. How to Integrate FAME I, FAME II and COURAGE?
  44. Importance of the Coronary Microvasculature
  45. FFR in Acute Coronary Syndrome: Culprit and Non-culprit Lesion
  46. FAME2 & COURAGE Trials: Going Functional, It\'s Solution!
  47. Update 2013: FFR-guided Decision Making
  48. Roles of FFR in Unstable Angina and NSTEMI
  49. Clinical Application of IMR : Evidence and Practice
  50. Sidebranch Compromise: Mechanism and Implication
  51. How and Why to Assess the Coronary Microvasculature
  52. Gap Between Anatomy and Function
  53. FFR Clinical Trials and Applications: Make the PCI Practice Changed
  54. Beyond FAME: The Integration of Invasive Ischemia Assessment(FFR) into Clinical Practice
  55. When to Use IVUS and When Would FFR Be a Better Choice?
  56. FFR Guided PCI
  57. Integrated Decision Making in Bifurcation Lesion (IVUS vs. FFR)
  58. Practice Guideline for FFR Use (FAME Study)
  59. FFR in Multivessel Disease: Results of the F.A.M.E. Multicenter, International, Randomized Study Comparing FFR Guided PCI to Angio Guided PCI in Patients with Multivessel CAD
  60. Fundamentals, Techniques, Pitfalls, and Limitations of FFR Interpretation and Measurement
  61. Fractional Flow Reserve: Concept and Practical Set Up
  62. FFR-Guided PCI
  63. FFR in Multivessel Disease: Results of the F.A.M.E. Multicenter, International, Randomized Study Comparing FFR guided PCI to Angio guided PCI in Patients with Multivessel CAD
  64. Physiologic Assessment of Coronary Microvascular Dysfunction
  65. Physiologic Study and PCI
Conference Slides
Category